Introduction Blood cancer survivors are at increased risk for medical complications. Methods Our questionnaire-based study involved 1,551 blood cancer survivors with a ≥3-year interval since the last intense treatment. Its goal was to quantify health-related complications during follow-up and assess their impact on the patients' lives. Results 20.4% of responding survivors reported a disease relapse, most often in indolent lymphomas. Second primary malignancies occurred in 14.1%, primarily in lymphoma and allogeneic transplantation survivors. The most frequent malignancy was basal cell carcinoma of the skin, but myeloid malignancies, melanoma, bladder, head-and-neck, and thyroid cancer also appeared disproportionately frequent. An increased infection rate was reported by 43.7%, most often after allogeneic transplantation. New cardiovascular diseases were reported by 30.2%, with a high rate of thromboembolic events in multiple myeloma and myeloproliferative diseases. Polyneuropathies were reported by 39.1%, most often by survivors with a history of multiple myeloma or aggressive lymphoma. Disease relapse was perceived as the highest burden, followed by second primary malignancy, increased infection frequency, and polyneuropathy. In each area investigated, the range of perceived severities was wide. Conclusions Health-related complications are frequent during blood cancer follow-up, with significant repercussions on the patients' lives.
Keyphrases
- young adults
- end stage renal disease
- multiple myeloma
- risk factors
- newly diagnosed
- ejection fraction
- stem cell transplantation
- chronic kidney disease
- cardiovascular disease
- bone marrow
- mental health
- healthcare
- depressive symptoms
- stem cells
- social support
- spinal cord injury
- acute myeloid leukemia
- metabolic syndrome
- mass spectrometry
- atrial fibrillation
- mesenchymal stem cells
- patient reported
- cell therapy
- wound healing
- cardiovascular risk factors
- papillary thyroid
- hematopoietic stem cell
- soft tissue
- single molecule